Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $183M | $131M | $213M | $257M | $176M | $235M | $141M | $46.8M | $29.6M | $6.44M |
| Revenue growth | — | -28.5% | 62.6% | 20.5% | -31.3% | 33.5% | -40.2% | -66.7% | -36.7% | -78.3% |
| Operating income | -$50.0M | -$117M | -$86.7M | -$89.3M | -$192M | -$289M | -$301M | -$323M | -$150M | -$45.9M |
| Operating margin | -27.3% | -89.5% | -40.7% | -34.8% | -108.8% | -122.6% | -213.9% | -689.5% | -507.8% | -712.7% |
| Net income | -$58.1M | -$121M | -$86.4M | -$77.0M | -$189M | -$290M | -$294M | -$284M | -$47.6M | $183M |
| Net margin | -31.7% | -92.3% | -40.6% | -30.0% | -107.4% | -123.3% | -208.7% | -607.3% | -160.6% | 2848.6% |
| EPS (diluted) | -$0.93 | -$1.66 | -$1.03 | -$0.89 | -$2.11 | -$3.14 | -$3.14 | -$2.92 | -$11.89 | $45.37 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $7.11M | -$66.5M | -$76.1M | -$78.7M | $81.6M | -$82.2M | -$146M | -$315M | -$138M | -$4.77M |
| Capital expenditures | $1.25M | $8.50M | $8.02M | $5.76M | $3.99M | $5.19M | $3.74M | $2.52M | $266K | $38.0K |
| Free cash flow | $5.86M | -$75.0M | -$84.2M | -$84.5M | $77.6M | -$87.4M | -$150M | -$318M | -$138M | -$4.81M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $174M | $674M | $89.3M | $126M | $678M | $171M | $156M | $81.6M | $50.5M | $47.9M |
| Total assets | $470M | $899M | $881M | $857M | $827M | $774M | $610M | $424M | $215M | $120M |
| Total liabilities | $294M | $351M | $352M | $322M | $385M | $545M | $612M | $586M | $398M | $115M |
| Long-term debt | — | — | — | — | — | — | — | — | — | $75.0M |
| Shareholders' equity | $156M | $528M | $509M | $516M | $422M | $209M | -$21.4M | -$204M | -$226M | -$30.0M |
| Retained earnings | -$510M | -$631M | -$716M | -$785M | -$974M | -$1.26B | -$1.56B | -$1.84B | -$1.89B | -$1.71B |
| Shares (wtd avg diluted) | 63.7M | 82.5M | 85.4M | 87.7M | 89.9M | 92.3M | 93.6M | 97.3M | 4.00M | 4.04M |
Every figure is extracted from KYNTRA BIO, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.